Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Stopeck, Alison; Rader, Michael; Henry, David; D. Danese, Mark; Halperin, Marc; Cong, Ze; Qian, Yi; Dansey, Roger; Chung, Karen

doi:10.3111/13696998.2012.675380

Public

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Published in Journal of Medical Economics • Mar 13, 2012

Authors:

Alison Stopeck

Michael Rader

David Henry

Abstract

OBJECTIVE: With increasing healthcare resource constraints, it has become important to understand the incremental cost-effectiveness of new medicines. Subcutaneous denosumab is superior to intravenous zoledronic acid (ZA) for the prevention of skeletal-related events (SREs) in patients with advanced...

Subject

Denosumab

Zoledronic acid

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!